Neumora Therapeutics

Edit info

Founded: 2020

Location: Watertown, MA

Employee range: 50 - 200

Clinical stage: Clin2

Therapy area: Depression

Drug types: NEU, PSY

Lead product: NMRA-140

Funding: $112M B Oct 2022; $500M A Oct 2021

Investors: Abu Dhabi Growth Fund (ADG), Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners

neumoratx.com

linkedin.com

job board

Drug notes:

NMRA-511 Clin1 anxiety; NMRA-M4R Clin0 neuropsychiatric disorders; NMRA-GRIN2A Clin0 neuropsychiatric disorders; 3 programs RD/Clin0 neurodegenerative diseases

About:

Neumora Therapeutics is a biopharmaceutical company founded to address the global brain disease crisis and improve patient lives through the development of targeted and effective neurodegenerative and neuropsychiatric therapies. Neumora’s therapeutics are aimed to target relevant pathways across various CNS diseases. They also leverage a precision medicine approach to identify patient populations of interest. Their research investigates the mechanisms of action behind major depressive disorder, schizophrenia, bipolar depression, Alzheimer’s, ALS, and Parkinson’s disease. Utilizing their precision medicine approach, Neumora is committed to discovering novel therapeutic targets and developing effective and meaningful therapies.